The mTOR inhibitor AZD8055 inhibits proliferation and glycolysis in cervical cancer cells

Oncology Letters

Volumn 5, Issue 2, 2013, Pages 717-721

  Li, Shaoru ^a   Li, Yan ^a   Hu, Ruili ^a   Li, Weihua ^b   Qiu, Haifeng ^c   Cai, Honghua ^a   Wang, Shijin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XINXIANG MEDICAL UNIVERSITY   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c Shanghai Municipal Key Clinical Specialty   (China)

Author keywords

Anticancer activity; AZD8055; Cervical cancer; Glycolysis; MTOR signaling; Proliferation

Indexed keywords

AZD 8055; LACTATE DEHYDROGENASE; LACTIC ACID; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MICRORNA 143; PROTEIN KINASE B;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; UTERINE CERVIX CANCER; WESTERN BLOTTING;

EID: 84871589318     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.1058     Document Type: Article

References (28)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
3. Toschi A, Lee E, Thompson S, et al: Phospholipase D-mTOR requirement for the Warburg effect in human cancer cells. Cancer Lett 299: 72-79, 2010.
4. Lee JW, Choi CH, Choi JJ, et al: Altered MicroRNA expression in cervical carcinomas. Clin Cancer Res 14: 2535-2542, 2008.
5. Liu H, Zhang SZ, Cai SR, Peng JP and Zheng S: Effect of microRNA143 expression on cell proliferation in colonic carcinoma. Zhonghua Zhong Liu Za Zhi 30: 498-501, 2008 (inChinese).
6. Guertin DA and Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell 12: 9-22, 2007.
7. Chresta CM, Davies BR, Hickson I, et al: AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 70: 288-298, 2010.
8. Rottiers V and Naar AM: MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol 13: 239-250, 2012.
9. Osaki M, Takeshita F, Sugimoto Y, et al: MicroRNA-143 regulates human osteosarcoma metastasis by regulating matrix metalloprotease-13 expression. Mol Ther 19: 1123-1130, 2011.
10. Kang S, Dong SM, Kim BR, et al: Thioridazine induces apoptosis by targeting the PI3K/Akt/mTOR pathway in cervical and endometrial cancer cells. Apoptosis 17: 989-997, 2012.
11. Osman A: MicroRNAs in health and disease-basic science and clinical applications. Clin Lab 58: 393-402, 2012.
12. Hudson RS, Yi M, Esposito D, et al: MicroRNA-106b-25 cluster expression is associated with early disease recurrence and targets caspase-7 and focal adhesion in human prostate cancer. Oncogene: Sep 17, 2012 (Epub ahead of print). doi: 10.1038/onc.2012.424.
13. Fang R, Xiao T, Fang Z, et al: MicroRNA-143 (miR-143) regulates cancer glycolysis via targeting hexokinase 2 gene. J Biol Chem 287: 23227-23235, 2012.
14. Fasolo A and Sessa C: Targeting mTOR pathways in human malignancies. Curr Pharm Des 18: 2766-2777, 2012.
15. Sheppard K, Kinross KM, Solomon B, Pearson RB and PhillipsWA: Targeting PI3 kinase/Akt/mTOR signaling in cancer. Crit Rev Oncog 17: 69-95, 2012.
16. Grzybowska-Izydorczyk O and Smolewski P: mTOR kinase inhibitors as a treatment strategy in hematological malignancies. Future Med Chem 4: 487-504, 2012.
17. Diaz-Padilla I, Duran I, Clarke BA and Oza AM: Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer. Cancer Treat Rev 38: 767-775, 2012.
18. Barnett CM: Everolimus: targeted therapy on the horizon for the treatment of breast cancer. Pharmacotherapy 32: 383-396, 2012.
19. Hill EK and Dizon DS: Medical therapy of endometrial cancer: current status and promising novel treatments. Drugs 72: 705-713, 2012.
20. Mathupala SP, Ko YH and Pedersen PL: Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 25: 4777-4786, 2006.
21. Vander Heiden MG, Cantley LC and Thompson CB: Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324: 1029-1033, 2009.
22. Ambros V: The functions of animal microRNAs. Nature 431: 350-355, 2004.
23. Li X, Zhang G, Luo F, et al: Identification of aberrantly expressed miRNAs in rectal cancer. Oncol Rep 28: 77-84, 2012.
24. White NM, Youssef YM, Fendler A, Stephan C, Jung K and Yousef GM: The miRNA-kallikrein axis of interaction: a new dimension in the pathogenesis of prostate cancer. Biol Chem 393: 379-389, 2012.
25. Ng EK, Tsang WP, Ng SS, et al: MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer. Br J Cancer 101: 699-706, 2009.
26. Michael MZ, SM OC, van Holst Pellekaan NG, Young GP and James RJ: Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 1: 882-891, 2003.
27. Jiang S, Zhang LF, Zhang HW, et al: A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells. EMBO J 31: 1985-1998, 2012.
28. Gregersen LH, Jacobsen A, Frankel LB, Wen J, Krogh A and Lund AH: microRNA-143 down-regulates Hexokinase 2 in colon cancer cells. BMC Cancer 12: 232, 2012.